Leaders in the biopharma world and scientific community are concerned about the appointment of Robert F. Kennedy Jr. to lead the Department of Health and Human Services by President-elect Donald Trump. Kennedy, an environmental lawyer and vaccine skeptic, could have a significant impact on drug development, public health policy, and basic research if confirmed by the Senate. Trump’s promise to let Kennedy “go wild” on health and medicine policy suggests he will have a wide-ranging influence on agencies like the FDA, CDC, and NIH. This news has provoked a range of reactions among leaders still absorbing the implications of Trump’s election victory.
Source link
Trump taps RFK Jr. for HHS: Scientists, pharma, biotechs react
